pipette
ESEspañol

Pathogenic human autoantibodies target the soluble CASPR2 ectodomain to induce network hyperexcitability

D. Serrenho, N. del Villar, V. Bueno, D. Fernandes, Q. Tutor-New, T. Kanekiyo, E. Wing, R. Williams, S. Steinke, L. F. Ribeiro, P. Pinheiro, E. Coutinho, S. R. Irani, A. L. Carvalho

PreprintBold claims, read critically

In the authors' words

The mechanisms by which autoantibodies contribute to antibody-mediated neurological diseases remain poorly understood. Autoantibodies targeting the extracellular domain of CASPR2 are found in patients with clinical features consistent with hyperexcitability, including neuromyotonia and seizures. These antibodies are reported to disrupt the functions of membrane-embedded CASPR2. However, given that CASPR2 is also detected in cerebrospinal fluid (CSF), which contains CASPR2 autoantibodies, targeting of CSF-shed CASPR2 may represent an additional pathogenic mechanism, introducing a novel paradigm of soluble antigen modulation by autoantibodies. Here, we found that patient-derived polyclonal and monoclonal CASPR2 antibodies enhanced neuronal network excitability and selectively amplified excitatory synaptic transmission in human and rat primary cortical neurons. In addition, CASPR2 antibodies impaired calcium homeostasis and altered the intrinsic properties of both excitatory and inhibitory neurons. Notably, these antibodies depleted CASPR2 from both neuronal culture medium and patient CSF, suggesting targeting of the shed CASPR2 ectodomain. Knockdown of plasma membrane calcium ATPase 2 (PMCA2), a reported target of the CASPR2 ectodomain, abrogated the observed effects of CASPR2 antibodies. Together, our findings identify shed CASPR2 as a underrecognized pathogenic target of CASPR2 autoantibodies and demonstrate that its neutralization disrupts PMCA2-mediated calcium regulation, driving neuronal network hyperexcitability. More broadly, we identify the neuronal sheddome as a source of autoantibody targets and soluble protein neutralization as a novel disease mechanism, highlighting shed CASPR2 as a potential biomarker and therapeutic target.

Main resultThe abstract does not state a limitation.

Appeared: Wednesday, November 18. bioRxiv. Preprint, not yet peer-reviewed.

DOI: 10.64898/2026.11.16.766757